Ciclesonide + Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Rhinitis, Allergic, Perennial

Conditions

Rhinitis, Allergic, Perennial

Trial Timeline

Dec 1, 2004 → Dec 1, 2005

NCT ID

NCT00659048

About Ciclesonide + Placebo

Ciclesonide + Placebo is a phase 3 stage product being developed by AstraZeneca for Rhinitis, Allergic, Perennial. The current trial status is completed. This product is registered under clinical trial identifier NCT00659048. Target conditions include Rhinitis, Allergic, Perennial.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00826969	Approved	Completed	Sep 1, 2008	Oct 1, 2011	Asthma
NCT00163449	Phase 3	Completed	Nov 1, 2005	May 1, 2007	Asthma
NCT00659503	Phase 3	Completed	Feb 1, 2005	Nov 1, 2005	Rhinitis, Allergic, Seasonal
NCT00163293	Phase 3	Completed	Jan 1, 2005	Apr 1, 2010	Asthma
NCT00659048	Phase 3	Completed	Dec 1, 2004	Dec 1, 2005	Rhinitis, Allergic, Perennial
NCT00659594	Phase 3	Completed	Nov 1, 2004	Sep 1, 2005	Rhinitis, Allergic, Seasonal
NCT00659750	Phase 3	Completed	Dec 1, 2003	Apr 1, 2005	Rhinitis, Allergic, Perennial
NCT00659841	Phase 3	Completed	Dec 1, 2003	Feb 1, 2005	Rhinitis, Allergic, Seasonal

Competing Products

20 competing products in Rhinitis, Allergic, Perennial

See all competitors

Product	Company	Stage	Hype Score
LY3650150 + Placebo + Standard therapy for INCS	Eli Lilly	Phase 3	77
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	77
ASP4070 + Placebo	Astellas Pharma	Phase 2	52
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	52
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	52
placebo, isotonic ciclesonide, hypotonic ciclesonide	Sumitomo Pharma	Approved	85
ciclesonide nasal aerosol + ciclesonide nasal spray	Sumitomo Pharma	Approved	85
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalation	Sumitomo Pharma	Phase 3	77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spray	Sumitomo Pharma	Phase 1	33
ciclesonide + mometasone	Sumitomo Pharma	Phase 3	77
DSP-3025 + Placebo	Sumitomo Pharma	Phase 1	33
ciclesonide nasal aerosol + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + Placebo	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mg	Sumitomo Pharma	Phase 3	77
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	77
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	77
ciclesonide HFA 160 μg	Sumitomo Pharma	Phase 3	77
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	77
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)	Glenmark Pharmaceuticals	Phase 2	52

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved